Longitude (Cayman)’s ARK Genomic Revolution ETF ARKG Stock Holding History

Longitude (Cayman)’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-87,000	Closed	-$2.5M	–	47
2024 Q1	$2.5M	Buy	87,000 +7,000	+9%	+$210K	1.95%	14
2023 Q4	$2.62M	Buy	80,000 +25,000	+45%	+$680K	1.52%	16
2023 Q3	$1.53M	Buy	55,000 +9,000	+20%	+$294K	0.97%	25
2023 Q2	$1.57M	Buy	46,000 +5,000	+12%	+$157K	1.19%	28
2023 Q1	$1.23M	Sell	41,000 -5,000	-11%	-$155K	1.08%	30
2022 Q4	$1.3M	Buy	46,000 +10,000	+28%	+$317K	1.66%	18
2022 Q3	$1.18M	Sell	36,000 -5,000	-12%	-$184K	1.88%	21
2022 Q2	$1.29M	Sell	41,000 -4,000	-9%	-$140K	1.92%	18
2022 Q1	$2.07M	Buy	45,000 +1,150	+3%	+$54.8K	1.96%	24
2021 Q4	$2.69M	Sell	43,850 -150	-0.3%	-$10.4K	1.43%	27
2021 Q3	$3.29M	Buy	44,000 +14,000	+47%	+$1.17M	1.45%	24
2021 Q2	$2.77M	Sell	30,000 -6,500	-18%	-$553K	1.32%	29
2021 Q1	$3.24M	Buy	36,500 +27,500	+306%	+$2.73M	1.24%	31
2020 Q4	$839K	Buy	+9,000	New	+$717K	0.4%	39

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Longitude (Cayman)'s ARKG Position: Q2 2024 in Review

Longitude (Cayman) sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 87,000 shares — an estimated $2.5M sold.

Longitude (Cayman) first reported a position in ARKG in Q4 2020 and held it in 14 quarters. The position peaked at $3.29M in Q3 2021. 261 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

Longitude (Cayman) reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
Longitude (Cayman) sold 87,000 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $2.5M.
Longitude (Cayman) first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 14 quarters.
Longitude (Cayman)'s ARK Genomic Revolution ETF position peaked at $3.29M in Q3 2021.
261 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Longitude (Cayman)'s 13F filing for Q2 2024, filed 23 Jul 2024.